SEARCH

SEARCH BY CITATION

References

  • 1
    Coleman MP,Estève J,Damiecki P,Arslan A,Renard H. Trends in cancer incidence and mortality. IARC Scientific Publications No. 121. Lyon: International Agency for Research on Cancer, 1993.
  • 2
    Diepgen TL,Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 ( Suppl 61): 16.
  • 3
    Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902.
  • 4
    Balch CM,Murad TM,Soong SJ,Ingalls AL,Halpern NB,Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978; 188: 73242.
  • 5
    Austin PF,Cruse CW,Lyman G,Schroer K,Glass F,Reintgen DSl. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994; 1: 48794.
  • 6
    Streetly A,Markowe H. Changing trends in the epidemiology of malignant melanoma: gender differences and their implications for public health. Int J Epidemiol 1995; 24: 897907.
  • 7
    Balch CM,Soong SJ,Gershenwald JE,Thompson JF,Reintgen DS,Cascinelli N,Urist M,McMasters KM,Ross MI,Kirkwood JM,Atkins MB,Thompson JA,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 362234.
  • 8
    Statius Muller MG,van Leeuwen PA,de Lange-De Klerk ES,van Diest PJ,Pijpers R,Ferwerda CC,Vuylsteke RJ,Meijer S. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer 2001; 91: 240108.
  • 9
    Vuylsteke RJ,Borgstein PJ,van Leeuwen PA,Gietema HA,Molenkamp BG,Statius Muller MG,van Diest PJ,van der Sijp JR,Meijer S. Sentinel lymph node tumour load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol 2005; 12: 4408.
  • 10
    Nathanson N. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 1976; 44: 6776.
  • 11
    Morton DL,Wanek L,Nizze JA,Elashoff RM,Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991; 214: 4919.
  • 12
    Al-Batran SE,Rafiyan MR,Atmaca A,Neumann A,Karbach J,Bender A,Weidmann E,Altmannsberger HM,Knuth A,Jäger E. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 2005; 65: 393741.
  • 13
    Romero P,Dunbar PR,Valmori D,Pittet M,Ogg GS,Rimoldi D,Chen JL,Lienard D,Cerottini JC,Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumour-specific cytolytic T lymphocytes. J Exp Med 1998; 188: 164150.
  • 14
    Haanen JB,Baars A,Gomez R,Weder P,Smits M,de Gruijl TD,von Blomberg BM,Bloemena E,Scheper RJ,van Ham SM,Pinedo HM,van den Eertwegh AJ. Melanoma-specific tumour-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006; 55: 4518.
  • 15
    Meyer D,Schubert J,Scholz C,Braun S,Schmidt RE. MHC-I antigen expression determines sensitivity of hematopoetic progenitor cells as targets for NK cells. Immunobiology 1997; 197: 494504.
  • 16
    Ruiter DJ,Mattijssen V,Broecker EB,Ferrone. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2: 3545.
  • 17
    Restifo NP,Marincola FM,Kawakami Y,Taubenberger J,Yannelli JR,Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 10008.
  • 18
    Ferrone S,Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 48794.
  • 19
    Kageshita T,Hirai S,Ono T,Hicklin DJ,Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999; 154: 74554.
  • 20
    Kalams SA,Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199204.
  • 21
    Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004; 4: 595602.
  • 22
    Villadangos JA. Presentation of antigens by MHC class II molecules: getting the most out of them. Mol Immunol 2001; 38: 32946.
  • 23
    Bernsen MR,Hakansson L,Gustafsson B,Krysander L,Rettrup B,Ruiter D,Hakansson A. On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases. Br J Cancer 2003; 88: 42431.
  • 24
    Korman AJ,Boss JM,Spies T,Sorrentino R,Okada K,Strominger JL. Genetic complexity and expression of human class II histocompatibility antigens. Immunol Rev 1985; 85: 4586.
  • 25
    Giles RC,Capra JD. Structure, function, and genetics of human class II molecules. Adv Immunol 1985; 37: 171.
  • 26
    van Houdt IS,Oudejans JJ,van den Eertwegh AJ,Baars A,Vos W,Bladergroen BA,Rimoldi D,Muris JJ,Hooijberg E,Gundy CM,Meijer CJ,Kummer JA. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 2005; 11: 640007.
  • 27
    Morton DL,Wen DR,Wong JH,Economou JS,Cagle LA,Storm FK,Foshag LJ,Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 3929.
  • 28
    Bladergroen BA,Strik MC,Bovenschen N,van Berkum O,Scheffer GL,Meijer CJ,Hack CE,Kummer JA. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol 2001; 166: 321825.
  • 29
    Kummer JA,Kamp AM,Tadema TM,Vos W,Meijer CJ,Hack CE. Localization and identification of granzymes A and B-expressing cells in normal human lymphoid tissue and peripheral blood. Clin Exp Immunol 1995; 100: 16472.
  • 30
    Stam NJ,Vroom TM,Peters PJ,Pastoors EB,Ploegh HL. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2: 11325.
  • 31
    Sernee MF,Ploegh HL,Schust DJ. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 1998; 35: 17788.
  • 32
    Muris JJ,Meijer CJ,Cillessen SA,Vos W,Kummer JA,Bladergroen BA,Bogman MJ,MacKenzie MA,Jiwa NM,Siegenbeek van Heukelom LH,Ossenkoppele GJ,Oudejans JJ. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004; 18: 58996.
  • 33
    Clemente CG,Mihm MC,Bufalino R,Zurrida S,Collini P,Cascinelli N. Prognostic value of tumour infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 130310.
  • 34
    Ladanyi A,Somlai B,Gilde K,Fejos Z,Gaudi I,Timar J. T-cell activation marker expression on tumour-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 2004; 10: 52130.
  • 35
    Taylor RC,Patel A,Panageas KS,Busam KJ,Brady MS. Tumour-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007; 25: 86975.
  • 36
    Robbins PA,McMichael AJ. Immune recognition of HLA molecules downmodulates CD8 expression on cytotoxic T lymphocytes. J Exp Med 1991; 173: 22130.
  • 37
    Behrens G,Li M,Smith CM,Belz GT,Mintern J,Carbone FR,Heath WR. Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol 2004; 82: 8490.
    Direct Link:
  • 38
    Ogino T,Bandoh N,Hayashi T,Miyokawa N,Harabuchi Y,Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 2003; 9: 404351.
  • 39
    Ogino T,Shigyo H,Ishii H,Katayama A,Miyokawa N,Harabuchi Y,Ferrone S. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006; 66: 92819.
  • 40
    Oudejans JJ,Jiwa NM,Kummer JA,Horstman A,Vos W,Baak JP,Kluin PM,van der Valk P,Walboomers JM,Meijer CJ. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein- Barr virus-positive and -negative Hodgkin's disease. Blood 1996; 87: 384451.
  • 41
    Rees RC,Mian S. Selective MHC expression in tumours modulates adaptive and innate anti-tumour responses. Cancer Immunol Immunother 1999; 48: 37481.
  • 42
    van den Elsen PJ,Holling TM,Kuipers HF,van der Stoep N. Transcriptional regulation of antigen presentation. Curr Opin Immunol 2004; 16: 6775.
  • 43
    Garrido F,Ruiz-Cabello F,Cabrera T,Pérez-Villar JJ,López-Botet M,Duggan-Keen M,Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 8995.
  • 44
    Ferrone S,Campoli M. A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. Exp Rev Dermatol 2006; 1: 80523.